Value Investor
Start free

Evommune

EVMN on NYSE. Pharmaceutical preparations. Market value $241m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-31.1%low

For every $100 of what the whole company costs, it produced $-31.12 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$6.61 a share, 9% above its 1-year low

Over the past year the price has ranged from $6.08 to $33.20.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.1
-0.1
202512 monthsto Jun '26
Revenue
$13m
Operating margin
-623.6%
Debt to equity
n/a
Shares outstanding
0.04bn

Health checks

  • Free cash flow positive0 of 1 years
  • Accounting checksSkipped: company is not yet profitable
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesRoughly flat

Dates

Next results (estimated)
n/a
Last annual report (10-K)
5 March 2026
Next quarterly (estimated, 10-Q)
5 November 2026

Who owns it

None of the long-term investors we follow own it. 105 funds in all.

Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

6 investors own more than 5%.

  • LSP 7 Cooperatieve U.A.
    Passive investor
    at least 14.7%−1.0 pts
    (filed with 1 related holder)
    Since 12 February 2026
  • Nan Fung Group Holdings Limited
    Passive investor
    at least 10.9%
    (filed with 12 related holders)
    Since 31 December 2025
  • at least 9.7%−1.3 pts
    (filed with 3 related holders)
    Since 12 February 2026
  • 5.4%
    Since 30 June 2026
  • at least 5.3%
    (filed with 2 related holders)
    Since 15 July 2026
  • Andera Partners
    Passive investor
    at least 3.9%−2.1 pts
    (filed with 3 related holders)
    Since 30 June 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 5 insiders bought $45m of shares on the open market. 6 sold $2m, $2m of it under preset trading plans.

  • Carver Kyle
    Chief Financial Officer
    Bought
    Date
    8 July 2026
    Shares
    1,000
    Price
    $13.26
    Value
    $13,260
  • KIRSCH ARTHUR S
    Director
    Bought
    Date
    7 July 2026
    Shares
    10,000
    Price
    $13.30
    Value
    $133,000
  • Patel Jeegar Pravinkumar
    Chief Scientific Officer
    Sold
    under a preset trading plan
    Date
    22 June 2026
    Shares
    1,488
    Price
    $22.50
    Value
    $33,480
  • Drew Janice Suzann
    Chief of Dev. Operations
    Sold
    under a preset trading plan
    Date
    22 June 2026
    Shares
    20,000
    Price
    $22.63
    Value
    $452,600
  • Pena Luis C.
    President & CEO, Director
    Sold
    under a preset trading plan
    Date
    22 June 2026
    Shares
    7,438
    Price
    $22.71
    Value
    $168,917
  • Cohen David E
    Director
    Sold
    under a preset trading plan
    Date
    2 June 2026
    Shares
    6,056
    Price
    $20.33
    Value
    $123,094
  • Patel Jeegar Pravinkumar
    Chief Scientific Officer
    Sold
    under a preset trading plan
    Date
    1 June 2026
    Shares
    16,687
    Price
    $22.74
    Value
    $379,462
  • Pena Luis C.
    President & CEO, Director
    Sold
    under a preset trading plan
    Date
    1 June 2026
    Shares
    16,787
    Price
    $22.74
    Value
    $381,736
  • Carver Kyle
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    28 May 2026
    Shares
    18,175
    Price
    $22.84
    Value
    $415,117
  • Moss Gregory S.
    Chief Business & Legal Officer
    Sold
    under a preset trading plan
    Date
    28 May 2026
    Shares
    14,223
    Price
    $22.83
    Value
    $324,711

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 5 Mar 2026, plus the 10-Q filed 6 Aug 2026 and 10 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.